Blood · 2022 · 47 citations · 30 references
MedicineImmunologyOncologyClinical ImmunologyImmunotherapyMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsPharmacodynamics Of ImmunotherapiesResponse AssessmentTargeted TherapyCheckpoint Inhibitor AntibodiesDaratumumab TherapyImmune Checkpoint Blockade CombinationsTargeted Therapy Mechanisms
Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting children. Although therapeutic strategies have improved, T-cell acute lymphoblastic leukemia (T-ALL) relapse is associated with chemoresistance and a poor prognosis. One strategy to overcome this obstacle is the application of monoclonal antibodies. Here, we show that leukemic cells from patients with T-ALL express surface CD38 and CD47, both attractive targets for antibody therapy. We therefore investigated the commercially available CD38 antibody daratumumab (Dara) in combination with a proprietary modified CD47 antibody (Hu5F9-IgG2σ) in vitro and in vivo. Compared with single treatments, this combination significantly increased in vitro antibody-dependent cellular phagocytosis in T-ALL cell lines as well as in random de novo and relapsed/refractory T-ALL patient-derived xenograft (PDX) samples. Similarly, enhanced antibody-dependent cellular phagocytosis was observed when combining Dara with pharmacologic inhibition of CD47 interactions using a glutaminyl cyclase inhibitor. Phase 2-like preclinical in vivo trials using T-ALL PDX samples in experimental minimal residual disease-like (MRD-like) and overt leukemia models revealed a high antileukemic efficacy of CD47 blockade alone. However, T-ALL xenograft mice subjected to chemotherapy first (postchemotherapy MRD) and subsequently cotreated with Dara and Hu5F9-IgG2σ displayed significantly reduced bone marrow infiltration compared with single treatments. In relapsed and highly refractory T-ALL PDX combined treatment with Dara and Hu5F9-IgG2σ was required to substantially prolong survival compared with single treatments. These findings suggest that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.
30
Ravindra Majeti, Mark P. Chao, Ash A. Alizadeh et al. · Cell · 2009 · 1.7K citations
Medicine, Hematology, Oncology +14
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal, Catriona Jamieson, Wendy W. Pang et al. · Cell · 2009 · 1.6K citations
Medicine, Cell Biology, Hematology +10
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text
Life Sciences, Immunology, Oncology +17
Torsten Haferlach, Alexander Kohlmann, Lothar Wieczorek et al. · Journal of Clinical Oncology · 2010 · 675 citations · Full text